H2-Pharma has acquired the exclusive rights to distribute fifteen products from Mayne Pharma, Inc.
In 2015 the combined market for these products was approximately $8.3 million according to IMS Health. H2-Pharma has already launched three (3) of these products and will launch the remaining in its own label by the end of 2016.
Bryce M. Harvey, H2-Pharma's President, stated, "We are pleased to add these products to our growing portfolio of commercial generic drugs. We continue to pursue opportunities to expand our generic business through strategic product acquisitions and distribution agreements. This transaction resonates with our primary goal at H2-Pharma, which is to bring value to our portfolio as well as to our partners' product portfolios by utilizing our extensive industry experience and knowledge. Our commitment is and will continue to be to foster innovation within our industry by developing new ideas and programs which will benefit each and every one of our partners."